Dr. Reddys Laboratories Ltd.

Dr Reddy’s is currently trading at Rs. 1957.50, up by 28.10 points or 1.46% from its previous closing of Rs. 1929.40 on the BSE.

The scrip opened at Rs. 1925.00 and has touched a high and low of Rs. 1968.60 and Rs. 1925.00 respectively. So far 11596 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1968.60 on 25-Jan-2013 and a 52 week low of Rs. 1528.00 on 19-Jun-2012.

Last one week high and low of the scrip stood at Rs. 1939.00 and Rs. 1880.00 respectively. The current market cap of the company is Rs. 33287.95 crore.

The promoters holding in the company stood at 25.56% while Institutions and Non-Institutions held 40.15% and 17.63% respectively.

Dr Reddy’s Laboratories has launched Desloratadine Orally Disintegrating Tablets (ODT) (2.5 mg & 5 mg), a bioequivalent generic version of Clarinex Reditabs (desloratadine) in the US market on January 24, 2013. Dr Reddy’s ANDA for Desloratadine ODT is approved by the United States Food & Drug Administration (USFDA). The company’s Desloratadine ODT 2.5 mg & 5 mg are available in unit dose packages of 30 (5x6).

The Clarinex Reditabs brand had US sales of approximately $5.3 million for the most recent twelve months ending November 2012 according to IMS Health.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.